Related Experiment Videos
Tandem transplantation in multiple myeloma
Javier Bolaños-Meade1, Gordon L Phillips, Ashraf Badros
1Bone Marrow Transplant Program, University of Maryland, Greenebaum Cancer Center, Blood and Marrow Transplant Program, Baltimore, Maryland, USA.
Oncology (Williston Park, N.Y.)
|March 29, 2003
Summary
High-dose chemotherapy with autologous stem cell transplant improves multiple myeloma outcomes but doesn't offer a cure. Tandem transplants show promise, especially for high-risk patients, but require further study.
Area of Science:
- Hematology
- Oncology
- Stem Cell Transplantation
Background:
- High-dose chemotherapy and autologous stem cell support have significantly improved outcomes for multiple myeloma patients.
- Complete remission rates range from 25% to 50%, with median disease-free and overall survival exceeding 3 and 5 years, respectively.
Purpose of the Study:
- To evaluate the efficacy of tandem transplants (autologous and allogeneic) in multiple myeloma.
- To identify patient subsets who benefit from intensified treatment strategies.
Main Methods:
- Review of outcomes with high-dose chemotherapy and autologous stem cell support.
- Analysis of tandem autologous transplant data and emerging data on tandem auto/allo transplants.
Main Results:
- Tandem autologous transplants may improve progression-free survival, with benefits apparent 3-5 years post-transplant.
- Good-risk patients with complete/near-complete response after the first transplant benefit most from a second cycle.
- High-risk patients with poor prognostic markers may benefit from novel approaches like tandem auto/allo transplants.
Conclusions:
- While autologous transplantation has advanced multiple myeloma treatment, it has not led to a cure.
- Tandem transplants, particularly auto/allo approaches, show promise for specific patient groups, especially high-risk individuals.
- Further investigation is needed to establish the efficacy and safety of tandem transplants, with current application primarily for high-risk patients.